



RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
h	R1	NISHINO, Y. <i>et al.</i> "Major Core Proteins, p24s, of Human, Simian, and Feline Immunodeficiency Viruses are Partly Expressed on the Surface of the Virus-Infected Cells" <i>Vaccine</i> , 1992, pp. 677-683, Vol. 10, No. 10.	
	R2	STEINMAN, R. <i>et al.</i> "Biochemical and Immunological Characterization of the Major Structural Proteins of Feline Immunodeficiency Virus" <i>Journal of General Virology</i> , 1990, pp. 701-706, Vol. 71.	
	R3	STRANDSTROM, H.V. <i>et al.</i> "Studies with Canine Sera that Contain Antibodies which Recognize Human Immunodeficiency Virus Structural Proteins" <i>Cancer Research</i> , 1990, pp. 5628s-5630s, Vol. 50.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner  
Signature

Date

Considered

3/23/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#11 +

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/080,772		
		Filing Date	February 22, 2002		
		First Named Inventor	Janet K. Yamamoto		
		Group Art Unit	1645		
		Examiner Name	unknown		
Sheet	1	of	1	Attorney Docket Number	UF-267XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ABBAS, A. K. <i>et al.</i> , In <u>Cellular and Molecular Immunology</u> , 4th edition, 2000, pp. 196-199, W.B. Saunders Company, Philadelphia.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	3/23/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

Sheet

1

of

2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1				
	U2				
	U3				
	U4				
	U5				
	U6				
	U7				
	U8				
	U9				
	U10				
	U11				
	U12				
	U13				
	U14				
	U15				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1	EP 0 860 504 A1	08-26-1998	Idexx Laboratories, Inc	All
	F2	WO 94/02613 A1	02-03-1994	Pitman-Moore, Inc.	All


Examiner  
SignatureDate  
Considered

3/13/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#13 +

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

Sheet

1

of

6

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
49	U1	US-4,358,535	11-09-1982	Falkow <i>et al.</i>	All
	U2	US-4,361,537	11-30-1982	Deutsch <i>et al.</i>	All
	U3	US-4,683,195	07-28-1987	Mullis <i>et al.</i>	All
	U4	US-4,683,202	07-28-1987	Mullis	All
	U5	US-4,708,818	11-24-1987	Montagnier <i>et al.</i>	All
	U6	US-4,800,159	01-24-1989	Mullis <i>et al.</i>	All
	U7	US-4,861,720	08-29-1989	Pedersen <i>et al.</i>	All
	U8	US-5,037,753	08-06-1991	Pedersen <i>et al.</i>	All
	U9	US-5,055,391	10-08-1991	Montagnier <i>et al.</i>	All
	U10	US-5,108,891	04-28-1992	Croxson	All
	U11	US-5,118,602	06-02-1992	Pedersen <i>et al.</i>	All
	U12	US-5,135,684	08-04-1992	Mohn <i>et al.</i>	All
	U13	US-5,160,701	11-03-1992	Brown, III <i>et al.</i>	All
	U14	US-5,275,813	01-04-1994	Yamamoto <i>et al.</i>	All
	U15	US-5,510,106	04-23-1996	Yamamoto <i>et al.</i>	All

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
49	F1	WO 99/60988 A2	12-02-1999	University of Florida	All	
	F2					
	F3					
	F4					


Examiner  
SignatureDate  
Considered

3/23/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

Sheet

2

of

6

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
[Signature]	U16	US-5,530,101	06-25-1996	Queen <i>et al.</i>	All
	U17	US-5,565,319	10-15-1996	Pedersen <i>et al.</i>	All
	U18	US-5,585,098	12-17-1996	Queen <i>et al.</i>	All
	U19	US-5,693,762	12-02-1997	Queen <i>et al.</i>	All
	U20	US-5,807,715	09-15-1998	Morrison <i>et al.</i>	All
	U21	US-5,846,825	12-08-1998	Yamamoto	All
	U22	US-5,922,533	07-13-1999	Vallari <i>et al.</i>	All
	U23	US-5,219,725	06-15-1993	O'Connor <i>et al.</i>	All
	U24	US-			
	U25	US-			
	U26	US-			
	U27	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F8					
	F9					
	F10					
	F11					
	F12					
	F13					
	F14					

Examiner  
SignatureDate  
Considered

3/21/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

Sheet 3 of 6

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ACKLEY, C. D. et al. "Immunologic Abnormalities in Pathogen-Free Cats Experimentally Infected with Feline Immunodeficiency Virus" <i>Journal of Virology</i> , 1990, pp. 5652-5655, Vol. 64, No. 11.	
	R2	AZOCAR, J. et al. "Susceptibility of Human Cell Lines to Feline Leukemia Virus and Feline Sarcoma Virus" <i>J. Natl Cancer Inst.</i> , 1979, pp. 1179-1184, Vol. 63, No. 5.	
	R3	BISHOP, S. A. et al. "Vaccination with Fixed Feline Immunodeficiency Virus (FIV) Infected Cells: Protection, Breakthrough and Specificity of Response" <i>Vaccine</i> , 1996, pp. 1243-1250, Vol. 14, No. 3.	
	R4	BUTERA, S. T. et al. "Survey of Veterinary Conference Attendees for Evidence of Zoonotic Infection by Feline Retroviruses" <i>J. Am. Vet. Med. Assoc.</i> , 2000, pp. 1475-1479, Vol. 217, No. 10.	
	R5	"HIV and Other Retroviruses" CDC Report, HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, pp. 1-20, <a href="http://www.cdc.gov/ncidod/dastlr/retrovirology/default.htm">www.cdc.gov/ncidod/dastlr/retrovirology/default.htm</a> .	
	R6	EGBERINK, H. F. et al. "Use of Western Blot and Radioimmunoprecipitation for Diagnosis of Feline Leukemia and Feline Immunodeficiency Virus Infections" <i>J. Am. Vet. Med. Assoc.</i> , 1991, pp. 1339-1342, Vol. 199, No. 10.	
	R7	GOUDSMIT, J. et al. "LAV/HTLV-III gag Gene Product p24 Shares Antigenic Determinants with Equine Infectious Anemia Virus but Not with Visna Virus or Caprine Arthritis Encephalitis Virus" <i>Intervirology</i> , 1986, pp. 169-173, Vol. 26.	
	R8	HOHDATSU, T. et al. "Genetic Subtyping and Epidemiological Study of Feline Immunodeficiency Virus by Nested Polymerase Chain Reaction-Restriction Fragment Length Polymorphism Analysis of the gag Gene" <i>J. Virol. Methods</i> , 1998, pp. 107-111, Vol. 70.	
	R9	HOSIE, M. J. et al. "Serological Responses of Cats to Feline Immunodeficiency Virus" <i>AIDS</i> , 1990, pp. 215-220, Vol. 4.	
	R10	JARRETT, O. et al. "Determinants of the Host Range of Feline Leukaemia Viruses" <i>J. Gen. Virol.</i> , 1973, pp. 169-175, Vol. 20.	
	R11	JOHNSTON, J. C. et al. "Minimum Requirements for Efficient Transduction of Dividing and Nondividing Cells by Feline Immunodeficiency Virus Vectors" <i>Journal of Virology</i> , 1999, pp. 4991-5000, Vol. 73, No. 6.	
	R12	JOHNSTON, J. et al. "Productive Infection of Human Peripheral Blood Mononuclear Cells by Feline Immunodeficiency Virus: Implications for Vector Development" <i>Journal of Virology</i> , 1999, pp. 2491-2498, Vol. 73, No. 3.	
	R13	KHABBAZ, R. F. et al. "Brief Report: Infection of a Laboratory Worker with Simian Immunodeficiency Virus" <i>The New England Journal of Medicine</i> , 1994, pp. 172-177, Vol. 330, No. 3.	

Examiner  
Signature

Date

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

6

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JP	R14	KHABBAZ, R. F. <i>et al.</i> "Simian Immunodeficiency Virus Needlestick Accident in a Laboratory Worker" <i>The Lancet</i> , 1992, pp. 271-273, Vol. 340, No. 8813.	
	R15	KAKINUMA, S. <i>et al.</i> "Nucleotide Sequence of Feline Immunodeficiency Virus: Classification of Japanese Isolates into Two Subtypes Which Are Distinct from Non-Japanese Subtypes" <i>Journal of Virology</i> , 1995, pp. 3639-3646, Vol. 69, No. 6.	
	R16	KOHLER, G. <i>et al.</i> "Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines by Cell Fusion" <i>Eur. J. Immunol.</i> , 1976, pp. 511-519, Vol. 6.	
	R17	LOUWAGIE, J. <i>et al.</i> "Phylogenetic Analysis of gag Genes from 70 International HIV-1 Isolates Provides Evidence for Multiple Genotypes" <i>AIDS</i> , 1993, pp. 769-780, Vol. 7, No. 6.	
	R18	MATSUO, K. <i>et al.</i> "Highly Conserved Epitope Domain in Major Core Protein p24 is Structurally Similar Among Human, Simian and Feline Immunodeficiency Viruses" <i>Journal of General Virology</i> , 1992, pp. 2445-2450, Vol. 73.	
	R19	MERRIFIELD, R. B. "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <i>J. Amer. Chem. Soc.</i> , 1963, pp. 2149-2154, Vol. 85.	
	R20	MORRISON, S. L. <i>et al.</i> "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains" <i>Proc. Natl. Acad. Sci. USA</i> , 1984, pp. 6851-6855, Vol. 81.	
	R21	MURPHY, F. A. <i>et al.</i> "Virus Taxonomy" In <i>Virology</i> , Second Edition, 1990, pp. 9-35, Raven Press, Ltd., New York.	
	R22	NORWAY, R. M. <i>et al.</i> "Thymic Lesions in Cats Infected with a Pathogenic Molecular Clone or an ORF-A/2-Deficient Molecular Clone of Feline Immunodeficiency Virus" <i>Journal of Virology</i> , 2001, pp. 5833-5841, Vol. 75, No. 13.	
	R23	OLMSTED, R. A. <i>et al.</i> "Molecular Cloning of Feline Immunodeficiency Virus" <i>Proc. Natl. Acad. Sci. USA</i> , 1989, pp. 2448-2452, Vol. 86, No. 7.	
	R24	OLMSTED, R. A. <i>et al.</i> "Nucleotide Sequence Analysis of Feline Immunodeficiency Virus: Genome Organization and Relationship to Other Lentiviruses" <i>Proc. Natl. Acad. Sci. USA</i> , 1989, pp. 8088-8092, Vol. 86, No. 20.	
R25	OU, C. Y. <i>et al.</i> "DNA Amplification for Direct Detection of HIV-1 in DNA of Peripheral Blood Mononuclear Cells" <i>Science</i> , 1988, pp. 295-297, Vol. 239, No. 4837.		
R26	PEDERSEN, N. C. <i>et al.</i> "Isolation of a T-Lymphotropic Virus From Domestic Cats with an Immunodeficiency-Like Syndrome" <i>Science</i> , 1987, pp. 790-793, Vol. 235, No. 4790.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. 01/18 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

5



of

6

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2002
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R27	POESCHLA, E. M. <i>et al.</i> "CXCR4 Is Required by a Nonprimate Lentivirus: Heterologous Expression of Feline Immunodeficiency Virus in Human, Rodent, and Feline Cells" <i>Journal of Virology</i> , 1998, pp. 6858-6866, Vol. 72, No. 8.	
	R28	PU, R. <i>et al.</i> "MHC-Restricted Protection of Cats Against FIV Infection by Adoptive Transfer of Immune Cells from FIV-Vaccinated Donors" <i>Cellular Immunology</i> , 1999, pp. 30-43, Vol. 198.	
	R29	PU, R. <i>et al.</i> "Dual-subtype FIV Vaccine Protects Cats Against <i>In Vivo</i> Swarms of Both Homologous and Heterologous Subtype FIV Isolates" <i>AIDS</i> , 2001, pp. 1225-1237, Vol. 15.	
	R30	RICHARDSON, J. <i>et al.</i> "Shared Usage of the Chemokine Receptor CXCR4 by Primary and Laboratory-Adapted Strains of Feline Immunodeficiency Virus" <i>Journal of Virology</i> , 1999, pp. 3661-3671, Vol. 73, No. 5.	
	R31	RIGBY, M. A. <i>et al.</i> "Evolution of Structural Proteins of Feline Immunodeficiency Virus: Molecular Epidemiology and Evidence of Selection for Change" <i>Journal of General Virology</i> , 1993, pp. 425-437, Vol. 74.	
	R32	RIGBY, M. A. <i>et al.</i> "Immunogenicity of a Peptide From a Major Neutralising Determinant of the Feline Immunodeficiency Virus Surface Glycoprotein" <i>Vaccine</i> , 1996, pp.1095-1102, Vol. 14, No. 12.	
	R33	SAIKI, R. K. <i>et al.</i> "Enzymatic Amplification of $\beta$ -Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sick Cell Anemia" <i>Science</i> , 1985, pp. 1350-1354, Vol. 230, No. 4732.	
	R34	SARMA, P. S. <i>et al.</i> "Feline Leukemia and Sarcoma Viruses: Susceptibility of Human Cells to Infection" <i>Science</i> , 1970, pp. 1098-1100, Vol. 168, No. 3935.	
	R35	SODORA, D. L. <i>et al.</i> "Identification of Three Feline Immunodeficiency Virus (FIV) <i>env</i> Gene Subtypes and Comparison of the FIV and Human Immunodeficiency Virus Type 1 Evolutionary Patterns" <i>Journal of Virology</i> , 1994, pp. 2230-2238, Vol. 68, No. 4.	
	R36	TALBOTT, R. L. <i>et al.</i> "Nucleotide Sequence and Genomic Organization of Feline Immunodeficiency Virus" <i>Proc. Natl. Acad. Sci. USA</i> , 1989, pp. 5743-5747, Vol. 86, No. 15.	
	R37	WILLETT, B. J. <i>et al.</i> "Shared Usage of the Chemokine Receptor CXCR4 by the Feline and Human Immunodeficiency Viruses" <i>Journal of Virology</i> , 1997, pp. 6407-6415, Vol. 71, No. 9.	
	R38	WILLETT, B. J. <i>et al.</i> "Common Mechanism of Infection by Lentiviruses" <i>Nature</i> , 1997, p. 587, Vol. 385, No. 6617.	
	R39	YAMAMOTO, J. K. <i>et al.</i> "Feline Immunodeficiency Syndrome—A Comparison Between Feline T-Lymphotropic Lentivirus and Feline Leukemia Virus" <i>Leukemia</i> , 1988, pp. 204S-215S, Vol. 2, No. 12 Supplement.	

Examiner  
Signature

Date

Considered


3/23/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 6 of 6

**Complete if Known**

Application Number	10/080,772
Filing Date	February 22, 2005
First Named Inventor	Janet K. Yamamoto
Group Art Unit	1645
Examiner Name	unknown
Attorney Docket Number	UF-267XC1

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
[Signature]	R40	YAMAMOTO, J. K. <i>et al.</i> "Pathogenesis of Experimentally Induced Feline Immunodeficiency Virus Infection in Cats" <i>Am. J. Vet. Res.</i> , 1998, pp. 1246-1258, Vol. 49, No. 8.	
	R41	YAMAMOTO, J. K. <i>et al.</i> "Epidemiologic and Clinical Aspects of Feline Immunodeficiency Virus Infection in Cats From the Continental United States and Canada and Possible Mode of Transmission" <i>J. Am. Vet. Med. Assoc.</i> , 1989, pp. 213-220, Vol. 194, No. 2.	
	R42	YAMAMOTO, J. K. <i>et al.</i> "Experimental Vaccine Protection Against Homologous and Heterologous Strains of Feline Immunodeficiency Virus" <i>Journal of Virology</i> , 1993, pp. 601-605, Vol. 67, No. 1.	
[Signature]	R43	JOHNSTON, J. B. <i>et al.</i> "Xenoinfection of Nonhuman Primates by Feline Immunodeficiency Virus" <i>Current Biology</i> , 2001, pp. 1109-1113, Vol. 11, No. 14.	
	R44		
	R45		
	R46		
	R47		
	R48		
	R49		
	R50		
	R51		
	R52		

TECH CENTER 1600/2900

AUG 14 2002

RECEIVED

Examiner  
SignatureDate  
Considered

3/25/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.